Sign In
30 Jun 2014 13:16
30 June 2014
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or "the Company")
Sector Reclassification
Advanced Oncotherapy (AIM: AVO), the developer of innovative radiation technology for cancer treatment, announces that it has received confirmation from FTSE Client Services that the Company has been reclassified as 4535 Medical Equipment from 8633 Real Estate Holding & Development, within the Industry Classification Benchmark categories of the London Stock Exchange.
The reclassification comes following the change of name to Advanced Oncotherapy plc (September 2012) and the disposal of the company's final healthcare property interests in December 2012. The company is now solely focused on developing and providing innovative medical technology for cancer treatment.
The reclassification will take effect immediately.
For further information contact:
Advanced Oncotherapy Plc | www.avoplc.com |
Sanjeev Pandya, CEO | Tel: +44 20 3617 8739 |
Westhouse Securities (Nomad & Joint Broker) | Tel: +44 20 7601 6100 |
Antonio Bossi / David Coaten | |
Peterhouse Corporate Finance (Joint Broker) | Tel: +44 20 7469 0930 |
Lucy Williams | |
Walbrook PR (Financial PR & IR) | |
Anna Dunphy/Mike Wort
| Tel: +44 20 7933 8780 or avo@walbrookpr.com |
About Advanced Oncotherapy
Vision:
To advance patients' clinical treatments and improve their everyday lives by harnessing innovative science and focusing it to develop the most effective and affordable cancer treatments.
Mission:
To facilitate the wider use of radiation with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.
Key corporate messages:
AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
AVO is a provider of proton radiotherapy that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.
AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care.
AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.
Through its shareholding and collaboration with Advanced Proton Solutions (APS), AVO can offer a complete turnkey solution to the design installation and operation of its LIGHT proton system for healthcare providers. This is attractive to potential purchasers and has led to its involvement in the development of the first comprehensive proton beam therapy centre in London to treat both NHS and private patients.
For more information, please visit http://www.avoplc.com
Follow the stocks
